Maximus publishes clinical research on the protocols we offer. This article summarizes the studies behind each protocol, the headline findings, and where to find the full data.
Why Maximus publishes research
Most telehealth companies rely entirely on existing manufacturer trials. Maximus publishes its own research on real-world client outcomes through our platform. This serves three purposes:
Demonstrates that our specific protocols produce measurable results
Documents safety profiles for the medications we prescribe
Provides a defensible basis for the claims we make in product and marketing copy
Our published studies are available at maximustribe.com/science-all.
Published studies by protocol
Enclomiphene Protocol
Largest dataset: N = 1,250 clients.
Key findings (averages):
Average free testosterone increased 89.7% (p < 0.001)
Average total testosterone increased 81.8% (p < 0.001)
73.5% of participants achieved the free testosterone benchmark for healthy non-obese 19–40 year old males
79.9% improved on a composite quality-of-life score (qADAM)
LH increased 87.1% on average — confirming the protocol preserves natural testosterone production
Source: Enclomiphene Protocol: Safe and Effective Therapy (Maximus, 2024).
Oral Testosterone
Three studies published:
Oral T monotherapy (N = 34) — HPTA non-suppression
100% of participants maintained LH/FSH (testicular function preserved)
Average free testosterone increased 129.8%
Oral T + Enclomiphene (N = 79)
Average 4x increase in total testosterone
Average 5x increase in free testosterone
100% of participants preserved fertility markers
Oral T liver safety (N = 100)
0 hepatic adverse events
Elevated liver enzymes at baseline improved over the course of the protocol
Source: Maximus white papers on Oral Native Testosterone.
Topical Testosterone with Enclomiphene
N = 45.
Average free testosterone increased 216%
100% of participants preserved fertility markers at enclomiphene doses ≥12.5mg
Source: Topical T with Enclomiphene: Preserving Fertility (Maximus, 2024).
Hair Improvement Protocol (Topical Dutasteride)
N = 15.
0% systemic side effects in the study
DHT reduced 20.4% (compared to 90–95% systemic DHT reduction with oral dutasteride — meaning significantly lower systemic exposure)
Source: Topical Dutasteride: Systemic Absorption and Side Effects (Maximus, 2024).
Oxytocin Calming Cream
N = 152 observation sets.
71% of participants improved on happiness scores (qADAM)
69% improved on sleep satisfaction (ISI)
Average nightly sleep duration increased approximately 25 minutes
0% reported morning brain fog
0% reported withdrawal or rebound symptoms
Non-habit-forming and non-sedating over 60 days of observation
Source: Novel Transdermal Oxytocin: Mood, Stress, and Sleep (Maximus, 2024).
Protocols based on established pharmacology
Some Maximus protocols use medications with extensive existing clinical evidence and are not the subject of a Maximus-published study. These include:
Weight Loss Protocol (semaglutide, tirzepatide) — backed by manufacturer trials and FDA-approved indications for weight management
Blood Flow Protocol (tadalafil, sildenafil, vardenafil) — decades of clinical use and an established safety profile
Sermorelin — well-established as a growth hormone-releasing hormone analog
Building Blocks — formulated to support general health markers; not the subject of a Maximus-specific trial
For protocol-specific safety, dosing, and what to expect, see the relevant protocol overview article.
Important context
Maximus studies are open-label observational studies of real-world clients on our platform, not placebo-controlled trials. Sample sizes range from 15 to over 1,250. Results reported are averages — individual response varies based on baseline health, adherence to the protocol, and other factors.
For the full studies, including methodology and limitations, visit maximustribe.com/science-all. For protocol-specific questions, message your clinician through your Maximus dashboard.